MAP2K7 and Hypertension: Overall, 8.1% of patients from the BRAF and MEK inhibitor treatment group had a decrease in LVEF compared with only 2.0% in the control group, and 19.5% of patients in the BRAF and MEK treatment group developed arterial hypertension, compared with 14.0% in the BRAF inhibitor control group.